Pharmaceutical

STAT+: In major test for prime editing, scientists succ...

Prime Medicine says its refinement of CRISPR passed the major test of correcting...

STAT+: ARPA-H head Renee Wegrzyn on the agency’s new Ca...

"We look for the areas that we see our asymmetrical investment can really advanc...

Opinion: Excited delirium: a deadly term finally laid t...

An emergency room doctor celebrates the end of the fake medical condition “excit...

Emergency medicine is grappling with a surprising probl...

While much of the health care workforce is battling staff shortages, the emergen...

Opinion: The pink ribbon of breast cancer awareness nee...

Men get breast cancer, too. The iconic pink ribbon needs a dash of blue to refle...

STAT+: ITC recommends partial import ban of Apple Watch...

Over the past three years, Masimo has been engaged in a bitter legal battle with...

ISN-001 by Anterogen for Burns: Likelihood of Approval

ISN-001 is under clinical development by Anterogen and currently in Phase II for...

Selinexor by Karyopharm Therapeutics for Wilms’ Tumor (...

Selinexor is under clinical development by Karyopharm Therapeutics and currently...

Itacitinib adipate by Incyte for Cytokine Release Syndr...

Itacitinib adipate is under clinical development by Incyte and currently in Phas...

Selinexor by Karyopharm Therapeutics for Atypical Terat...

Selinexor is under clinical development by Karyopharm Therapeutics and currently...

Denifanstat by Sagimet Biosciences for Breast Cancer: L...

Denifanstat is under clinical development by Sagimet Biosciences and currently i...

Sotigalimab by Pyxis Oncology for Anaplastic Astrocytom...

Sotigalimab is under clinical development by Pyxis Oncology and currently in Pha...

Sotigalimab by Pyxis Oncology for Astrocytoma: Likeliho...

Sotigalimab is under clinical development by Pyxis Oncology and currently in Pha...

Sotigalimab by Pyxis Oncology for Glioblastoma Multifor...

Sotigalimab is under clinical development by Pyxis Oncology and currently in Pha...

Sotigalimab by Pyxis Oncology for Glioma: Likelihood of...

Sotigalimab is under clinical development by Pyxis Oncology and currently in Pha...

Sotigalimab by Pyxis Oncology for Esophageal Cancer: Li...

Sotigalimab is under clinical development by Pyxis Oncology and currently in Pha...